Who: Akari Therapeutics/Peak Bio
What: Two struggling, publicly traded biotechs will combine in an all-stock merger of equals.
Akari, Peak Bio Hatch Merger Plan To Survive Together
Deal snapshot: Akari, which has stayed afloat through small financings in recent years, and Peak Bio, after going public via the SPAC route in 2022, will merge as equals and then prioritize their pipeline.
More from Strategy
More from Business
• By
Multi-blockbuster falls short in a giant cell arteritis study.
• By
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
• By
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.